Study of Plasma Brain-Derived Tau Changes in 100 Adults With Acute Ischemic Stroke Within 9 Hours of Onset

What this Trial Is About

Researchers are investigating brain-derived tau BD-tau as a blood-based biomarker for brain injury in acute ischemic stroke. Previous studies showed BD-tau levels correlate with brain injury and can predict functional outcomes, but the timing and progression of BD-tau changes after stroke onset are not fully understood. This study aims to track BD-tau levels hourly from admission up to 48 hours after stroke onset to better understand when BD-tau rises and plateaus. The study will include 100 patients diagnosed with acute ischemic stroke caused by a large- or medium-vessel occlusion within 9 hours of symptom onset. BD-tau and other brain injury markers like Neurofilament Light Chain will be measured every hour from admission to 48 hours after stroke onset using a blood test. Clinical data and neuroimaging results will be collected during hospitalization, and patients will be followed up clinically at 3 months. Participants will undergo frequent blood sampling to monitor BD-tau levels and have imaging assessments upon admission. Researchers will evaluate brain injury and infarct progression using CT and MRI scans, along with functional outcomes at 7 and 90 days after stroke. The study focuses on understanding the evolution of BD-tau as a marker of brain injury and its relationship with stroke progression and recovery over time.

PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke